Cancer Therapy

Immunome has successfully priced a public offering, raising approximately $400 million to advance its targeted cancer therapy development. The funds will fuel the advancement of its pipeline, including late-stage drug varegacestat, ROR1 ADC IM-1021, and FAP-targeted radiotherapy IM-3050, as well as early-stage ADC programs. This capital injection signifies strong investor confidence in the company’s innovative oncology approach.

Nuvalent, Inc. (NUVL) announced a public offering of 4,950,496 Class A common stock shares at $101.00 per share, anticipating gross proceeds of approximately $500 million. Selling Stockholders granted underwriters an option to purchase up to 742,574 additional shares. J.P. Morgan, Jefferies, TD Cowen, and Cantor are joint book-running managers. The offering is expected to close on November 20, 2025, pending standard conditions. Funds will support Nuvalent’s kinase-driven cancer therapies pipeline. The offering is under a shelf registration statement filed with the SEC.